# INTREPId (INTermediate Risk Erection PreservatIon Trial)

> **NCT04025372** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 234 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** GnRH Agonist
- **RADIATION:** Radiation Therapy
- **DRUG:** Darolutamide

## Key facts

- **NCT ID:** NCT04025372
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04025372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04025372, "INTREPId (INTermediate Risk Erection PreservatIon Trial)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04025372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*